Older adults and people with certain medical conditions are more likely to receive the respiratory syncytial virus (RSV) ...
Population-based analyses of new vaccination programmes provide robust real-world evidence for post-licensure vaccine ...
The risk for new-onset or recurrent AF was not increased among older adult patients with preexisting conditions following RSV vaccination.
The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...
The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...
Pfizer Inc. has announced that the European Commission (EC) has issued a decision amending the marketing authorization for ...
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing ...
"This approval underscores our commitment to protecting older adults from RSV-related respiratory diseases. We look forward to supplying mRESVIA from our Melbourne facility to older Australians ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results